cytosine has been researched along with Vulvar Neoplasms in 10 studies
Vulvar Neoplasms: Tumors or cancer of the VULVA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Secondary outcomes were toxic effects (to assess safety) and adherence to treatment (to assess feasibility)." | 2.79 | Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. ( Dutton, P; Fiander, A; Griffiths, G; Hibbitts, S; Hurt, CN; Jones, S; Madden, T; Man, S; Naik, R; Nordin, AJ; Powell, N; Tristram, A, 2014) |
| " Treatment was well tolerated with most common adverse events being mild to moderate affecting lesional skin: pain/burning/irritation (25 patients) and ulceration (13 patients)." | 2.78 | Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. ( Aboulafia, D; Berry, JM; Da Costa, M; Darragh, TM; Einstein, MH; Goldstone, SE; Jay, N; Lee, JY; Palefsky, JM; Panther, L; Stier, EA; Wilkin, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, SEF | 1 |
| Hibbitts, S | 2 |
| Hurt, CN | 2 |
| Bryant, D | 1 |
| Fiander, AN | 1 |
| Powell, N | 2 |
| Tristram, AJ | 1 |
| Mahner, S | 1 |
| Wölber, L | 1 |
| Tristram, A | 2 |
| Madden, T | 1 |
| Man, S | 1 |
| Dutton, P | 1 |
| Jones, S | 1 |
| Nordin, AJ | 1 |
| Naik, R | 1 |
| Fiander, A | 2 |
| Griffiths, G | 1 |
| Pepas, L | 2 |
| Kaushik, S | 2 |
| Nordin, A | 2 |
| Bryant, A | 2 |
| Lawrie, TA | 2 |
| Chakrabarti, M | 1 |
| Calista, D | 1 |
| Gormley, RH | 1 |
| Kovarik, CL | 1 |
| Stier, EA | 1 |
| Goldstone, SE | 1 |
| Einstein, MH | 1 |
| Jay, N | 1 |
| Berry, JM | 1 |
| Wilkin, T | 1 |
| Lee, JY | 1 |
| Darragh, TM | 1 |
| Da Costa, M | 1 |
| Panther, L | 1 |
| Aboulafia, D | 1 |
| Palefsky, JM | 1 |
| Koonsaeng, S | 1 |
| Verschraegen, C | 1 |
| Freedman, R | 1 |
| Bossens, M | 1 |
| Kudelka, A | 1 |
| Kavanagh, J | 1 |
| Sittisomwong, T | 1 |
| DeClercq, E | 1 |
| Snoeck, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women[NCT00550589] | Phase 2 | 33 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who cleared HPV among those who had a complete or partial response (NCT00550589)
Timeframe: 6 weeks after treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Cidofovir | 2 |
Number of patients with HPV16 at baseline in perianal HSIL and normal perianal tissue (NCT00550589)
Timeframe: Baseline
| Intervention | participants (Number) |
|---|---|
| Cidofovir | 16 |
Number of patients with HPV16 type present in the anus from anal swab or cytobrush at baseline (NCT00550589)
Timeframe: Baseline
| Intervention | participants (Number) |
|---|---|
| Cidofovir | 14 |
(NCT00550589)
Timeframe: 6 weeks after treatment discontinuation
| Intervention | proportion of participants (Number) |
|---|---|
| Cidofovir | 0.515 |
Number of study patients who had a serious adverse event (NCT00550589)
Timeframe: Every 2 weeks on study, 6 weeks after treatment discontinuation
| Intervention | participants (Number) |
|---|---|
| Cidofovir | 3 |
3 reviews available for cytosine and Vulvar Neoplasms
| Article | Year |
|---|---|
Medical interventions for high-grade vulval intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Car | 2015 |
Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.
Topics: Adult; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; Disease Progr | 2016 |
Human papillomavirus-related genital disease in the immunocompromised host: Part II.
Topics: Adjuvants, Immunologic; Alphapapillomavirus; Aminoquinolines; Antineoplastic Agents, Phytogenic; Ant | 2012 |
3 trials available for cytosine and Vulvar Neoplasms
| Article | Year |
|---|---|
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cidofovir | 2014 |
Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.
Topics: Acquired Immunodeficiency Syndrome; Administration, Cutaneous; Adult; Aged; Antiviral Agents; Anus N | 2013 |
Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Carcinoma in Situ; Cidofovir; Cytosine; | 2005 |
4 other studies available for cytosine and Vulvar Neoplasms
| Article | Year |
|---|---|
Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3.
Topics: Aminoquinolines; Biomarkers; Carcinoma in Situ; Cidofovir; Cytosine; DNA Methylation; DNA, Viral; Dr | 2017 |
Surgery or topical therapy for vulval intraepithelial neoplasia.
Topics: Aminoquinolines; Carcinoma in Situ; Cidofovir; Cytosine; Female; Humans; Imiquimod; Organophosphonat | 2014 |
Topical 1% cidofovir for the treatment of vulvar intraepidermal neoplasia (VIN1) developed on lichen sclerosus.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Cidofovir; Cytosine; Female; Humans; Organopho | 2009 |
Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir.
Topics: Administration, Oral; Administration, Topical; Adult; Antineoplastic Agents; Carcinoma in Situ; Cido | 2001 |